课题基金 / 基金详情

项目摘要

项目成果

Robert G. Whalen的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请人提供):HIV-1流行病在2007年导致约270万新感染,共有约3300万艾滋病毒/艾滋病感染者。临床试验表明,HIV-1感染不能通过用病毒包膜(Env)蛋白的单体重组形式免疫来预防。然而,很明显,HIV-1 Env含有可以诱导中和抗体的表位,并且这种抗体可以保护灵长类动物免受感染。 在先前的动物和人类研究中,单体gp 120在诱导中和抗体方面无效有几个原因。表面暴露的可变序列围绕CD 4结合位点,可能限制B细胞接近该表位。gp 120蛋白携带表位,如V3环,其具有免疫原性,但不暴露于天然病毒Env结构中的抗体。 两个主要的假设为HIV-1疫苗的免疫原设计提供了信息。第一种假设集中于由单克隆抗体定义的广泛中和表位。假设合适的免疫原将暴露这些表位并诱导具有与单克隆抗体相当的中和特异性的多克隆抗体。第二个假设表明,单一的广泛交叉反应的中和特异性是不容易诱导和多个表位必须识别抑制病毒的感染性。 这两种假设都可以通过设计和产生缺乏可变序列的基于Env的免疫原来测试,所述可变序列可能是免疫显性的,并且在任何情况下都不能诱导广泛的中和活性。去除可变区,同时保留CD 4结合活性可能会暴露这个重要的表位以及其他驻留在Env相对保守区域的表位。这种方法代表了递归过程中的第一步,以建立免疫原应具有的特征的概念或设计。 然而,一个单一的原型序列的实验测试不允许一个强大的概念评价。本提案中使用的另一种方法是为给定的疫苗概念创建序列变体,并测试许多这些变体。以这种方式,可以获得更大和更重要的数据集,从中得出关于免疫原设计的价值的结论。在本提案中,我们将尝试克服gp 120作为免疫原的一些局限性。我们认识到,免疫原形式,如可溶性三聚体模拟物或携带gp 120的病毒样颗粒可能最终需要有效的Env疫苗。 本提案的具体目标如下:(1)将修饰引入gp 120并评估其对配体结合特性的影响;(2)创建gp 120变体的组合文库并鉴定具有CD 4结合活性的变体;(3)用选定的gp 120变体免疫家兔并评估中和活性 如果gp 120变体能够诱导中和抗体,那么额外的研究将构成II期SBIR提案的基础。 公共卫生相关性:2007年,艾滋病毒/艾滋病流行病导致200万人死亡,270万人新感染,使艾滋病毒/艾滋病感染者总数接近3 300万人。研制疫苗被认为是减缓这一流行病所需的公共卫生措施的一个重要组成部分。这项研究计划旨在创造一种疫苗,可以诱导能够预防艾滋病毒感染的抗体。
英文摘要
DESCRIPTION (provided by applicant): The HIV-1 epidemic has resulted in ~2.7 million new infections in 2007 for a total of ~33 million people living with HIV/AIDS. Clinical trials have shown that HIV-1 infection cannot be prevented by immunization with monomeric recombinant forms of viral envelope (Env) proteins. However, it is clear that the HIV-1 Env contains epitopes that can induce neutralizing antibodies and that such antibodies can protect primates from infection. There are several reasons why monomeric gp120 has been ineffective at inducing neutralizing antibodies in previous animal and human studies. The surface-exposed variable sequences surround the CD4 binding site and might restrict B-cell access to this epitope. The gp120 protein carries epitopes such as the V3 loop that are immunogenic but not exposed to antibodies in the native virus Env structure. Two main hypotheses inform the design of immunogens for HIV-1 vaccines. The first hypothesis focuses on broadly neutralizing epitopes defined by monoclonal antibodies. It is hypothesized that suitable immunogens will expose these epitopes and induce polyclonal antibodies with neutralizing specificities comparable to those of the monoclonals. The second hypothesis suggests that a single broadly cross-reactive neutralizing specificity is not be readily induced and that multiple epitopes must be recognized to inhibit virus infectivity. Both hypotheses can be tested by the design and creation of Env-based immunogens lacking variable sequences that might be immunodominant and in any case cannot induce broad neutralizing activity. Removal of variable regions while retaining CD4 binding activity might expose this important epitope as well as others that reside in the relative conserved regions of Env. This approach represents an initial step in a recursive process to build upon a concept, or design, of what features an immunogen should possess. However, experimental testing of a single prototype sequence does not allow a robust evaluation of the concept. An alternative approach, used in this Proposal, is to create sequence variants for a given vaccine concept and to test a number of those variants. In this way, a larger and more significant dataset can be obtained from which to draw conclusions regarding the value of the immunogen design. In this Proposal, we will attempt to overcome some of the limitations of gp120 as an immunogen. We recognize that an immunogen format such as a soluble trimer mimic or a virus-like particle carrying gp120 might ultimately be required for an effective Env-based vaccine. The specific aims of this Proposal are as follows: (1) incorporate modifications into gp120 and evaluate their effect on ligand binding properties; (2) create combinatorial libraries of gp120 variants and identify those with CD4 binding activity; (3) immunize rabbits with selected gp120 variants and evaluate the neutralizing activity If the gp120 variants are able to induce neutralizing antibodies, then additional studies will form the basis of a Phase II SBIR proposal. PUBLIC HEALTH RELEVANCE: The HIV/AIDS epidemic has resulted in 2 million deaths and 2.7 million new infections in 2007, for a total of nearly 33 million people living with HIV/AIDS. Development of a vaccine is considered to be an essential component of the public health measures needed to slow the epidemic. This research proposal is designed to create a vaccine that can induce antibodies capable of preventing infection by the HIV virus.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Novel Therapeutic Vaccines for Chronic HBV
  • 批准号:
    8394626
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Novel Tetravalent Vaccines for Dengue Virus
  • 批准号:
    8315393
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
  • 批准号:
    8329484
  • 项目类别:
  • 资助金额:
    $30.0万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
Germline-Specific Immunogens for the Induction of Neutralizing Antibodies to HIV-
  • 批准号:
    8410439
  • 项目类别:
  • 资助金额:
    $59.78万
  • 财政年份:
    2012
  • 负责人:
    Robert G. Whalen
  • 依托单位:
海外基金